Combined preoperative xeloda and radiotherapy for lower rectal cancer.
- Author:
Chao-ping ZHUANG
1
;
Ting-han LI
;
Jun-wei WU
;
Gao-yang CAI
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Antimetabolites, Antineoplastic; therapeutic use; Capecitabine; Combined Modality Therapy; Deoxycytidine; adverse effects; analogs & derivatives; therapeutic use; Female; Fluorouracil; analogs & derivatives; Humans; Male; Middle Aged; Postoperative Complications; etiology; Radiotherapy; adverse effects; Rectal Neoplasms; therapy
- From: Chinese Journal of Oncology 2003;25(6):602-603
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the effect of combined preoperative xeloda and pelvic radiotherapy on locally advanced lower rectal cancer.
METHODSSixty lower rectal cancer patients were divided randomly into two groups. 30 patients (Group A) were treated with operation alone and 30 patients (Group B) were treated with xeloda and radiotherapy before operation.
RESULTSThe operative resection, anal preservation and local recurrence rates were 86.66%, 33.33%, 15.38% in group A and 100%, 83.33%, 0% in group B (P < 0.05 and P < 0.01).
CONCLUSIONCombined preoperative xeloda and radiotherapy for lower rectal cancer is able to significantly improve the operative resection, anal preservation and decrease the local recurrence rates.
